this post was submitted on 25 Aug 2024
238 points (99.6% liked)

Health - Resources and discussion for everything health-related

2231 readers
1 users here now

Health: physical and mental, individual and public.

Discussions, issues, resources, news, everything.

See the pinned post for a long list of other communities dedicated to health or specific diagnoses. The list is continuously updated.

Nothing here shall be taken as medical or any other kind of professional advice.

Commercial advertising is considered spam and not allowed. If you're not sure, contact mods to ask beforehand.

Linked videos without original description context by OP to initiate healthy, constructive discussions will be removed.

Regular rules of lemmy.world apply. Be civil.

founded 1 year ago
MODERATORS
 

A team of researchers in Kansai is set to begin clinical trials next month to develop medicine to help grow teeth.

The researchers, including from Kitano Hospital and Kyoto University Hospital, will conduct trials for teething medicine, aimed at treating people with congenital anodontia who are born with few teeth.

To check its safety, the experimental drug will first be administered to adult men who have lost back teeth, before it is tested on children with congenital anodontia. The team aims to put the treatment into practical use in around 2030.

you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 2 points 3 months ago (2 children)

It's really weird though. Why specify that you're targeting specifically kids with a disorder when your treatment is being tested on adults, and would work on any adult who has lost teeth for any reason?

[–] [email protected] 1 points 3 months ago (1 children)

Speculating, but probably because kids without any teeth and a genetic basis of that disease would pay for this treatment out of medical coverage, not dental coverage, at least in the US, and getting it approved for specifically that indication is easier, faster, and likely higher profit than the admittedly larger population but smaller insured availability of funds that would be the dental market.

Markets shouldn’t drive drug research, public health benefit should, but shrugs

[–] [email protected] 2 points 3 months ago (1 children)

Good thought, but it looks like they're a Japanese team conducting trials in Japan, so the US excuse for an insurance system shouldn't be a factor? IDK

[–] [email protected] 2 points 3 months ago

Quick search tells me that they have a national dental plan that covers 70%, but has limits on which procedures materials etc are covered. In other words, they may not cover this procedure if it’s more expensive than a traditional implant.

Additionally, there’s harmonization efforts between Japan and the US FDA; if fully expect they’re running clinical trials in JP with hopes for a later release abroad, and the US is a huge market so they’d still be angling that I’d think.

[–] [email protected] 1 points 3 months ago (1 children)

Because /hobthrob is incorrect. This medication will not and cannot be used to regrow teeth in people that don't have the genetic disorder "congenital anodontia". The drug can only help that >1% with the disorder.

[–] [email protected] 1 points 3 months ago* (last edited 3 months ago)

That's not what the article says though